4.5 Article

Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study

Journal

JOURNAL OF ALZHEIMERS DISEASE
Volume 90, Issue 2, Pages 761-773

Publisher

IOS PRESS
DOI: 10.3233/JAD-220432

Keywords

Cognition; neurodegeneration; oxidative stress; uric acid

Categories

Funding

  1. National Natural Science Foundation of China [82071201, 81971032]
  2. Shanghai Municipal Science and Technology Major Project [2018SHZDZX01]
  3. Shanghai Talent Development Funding for The Project [2019074]
  4. Research Start-up Fund of Huashan Hospital [2022QD002]
  5. Excellence 2025 Talent Cultivation Program at Fudan University [3030277001]
  6. ZHANGJIANG LAB
  7. Tianqiao and Chrissy Chen Institute
  8. State Key Laboratory of Neurobiology and Frontiers Center for Brain Science of Ministry of Education, Fudan University

Ask authors/readers for more resources

This study found that decreased levels of serum UA were correlated with Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, frontotemporal dementia, and dementia with Lewy bodies. Additionally, serum UA levels were positively correlated with cognitive levels in all patients.
Background: Excessive oxidative stress may contribute to neurodegeneration by leading to protein aggregation and mitochondrial dysfunction. Uric acid (UA) is an important endogenous antioxidant that protects against oxidative stress, yet its exact role in neurodegeneration remains unclear. Objective: To explore the performance of serum UA in neurodegenerative disorders. Methods: A total of 839 controls and 840 patients, including Alzheimer's disease (AD), Parkinson's disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), motor neuron disease (MND), Creutzfeldt-Jakob disease (CJD), and mixed dementia (MixD) were enrolled. Fasting serum UA levels were measured in all participants and compared between patients and controls. Linear regression models were utilized to explore possible relationships of serum UA with cognition, disease duration, age, and age of onset. Results: Compared to controls (355.48 +/- 85.38 mu mol/L), serum UA was significantly lower in AD (291.29 +/- 83.49 mu mol/L, p < 0.001), PD (286.95 +/- 81.78 mu mol/L, p < 0.001), PSP (313.32 +/- 88.19 mu mol/L, p < 0.001), FTD (313.89 +/- 71.18 mu mol/L, p = 0.001), and DLB (279.23 +/- 65.51 mu mol/L, p < 0.001), adjusting for confounding factors including age, gender, education, etc. In addition, serum UA was positively correlated with cognitive levels in all patients (Mini-Mental State Examination: r = 0.136, p = 0.001; and Montreal Cognitive Assessment Scale: r = 0.108, p = 0.009). Conclusion: Decreased levels of serum UA were correlated with AD, PD, PSP, FTD, and DLB, offering significant potential as a promisingly relevant, less-invasive marker of multiple neurodegenerative disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available